The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Background First-line imatinib treatment can be successfully discontinued in patients with
chronic myeloid leukaemia after deep molecular response has been sustained for at least 2 …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Abstract Prognosis of Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) in the
elderly has improved during the imatinib era. We investigated dasatinib, another potent …

Background Ponatinib has shown potent activity against chronic myeloid leukaemia that is
resistant to available treatment, although it is associated with arterial occlusion. We …

Genomic events associated with poor outcome in chronic myeloid leukemia (CML) are
poorly understood. We performed whole-exome sequencing, copy-number variation, and/or …

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …

Abstract The 2-aminothiazole (2-AT) core is an active pharmacophore and used in medicinal
chemistry and drug discovery research. A number of drugs with 2-AT core are in the market …